Overview
On 26 March 2014, orphan designation (EU/3/14/1255) was granted by the European Commission to Boehringer Ingelheim International GmbH, Germany, for volasertib for the treatment of acute myeloid leukaemia.
Key facts
Active substance |
Volasertib
|
Intended use |
Treatment of acute myeloid leukaemia
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/14/1255
|
Date of designation |
26/03/2014
|
Sponsor |
Boehringer Ingelheim International GmbH
Binger Strasse 173 D-55216 Ingelheim am Rhein Germany Tel. +49 613 2770 Fax +49 613 2720 E-mail: qrpegra.de@boehringer-ingelheim.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: